First Time Loading...

Regeneron Pharmaceuticals Inc
NASDAQ:REGN

Watchlist Manager
Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Watchlist
Price: 903.48 USD 1.44% Market Closed
Updated: May 2, 2024
Section:
 

Wall Street
Price Targets

REGN Price Targets Summary
Regeneron Pharmaceuticals Inc

Wall Street analysts forecast REGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for REGN is 1 069.29 USD with a low forecast of 727.2 USD and a high forecast of 1 248.45 USD.

REGN Lowest Forecast
Wall Street Target
727.2 USD
20% Downside
REGN Average Forecast
Wall Street Target
1 069.29 USD
18% Upside
REGN Highest Forecast
Wall Street Target
1 248.45 USD
38% Upside
Lowest
Price Target
727.2 USD
20% Downside
Average
Price Target
1 069.29 USD
18% Upside
Highest
Price Target
1 248.45 USD
38% Upside

REGN Last Price Targets
Regeneron Pharmaceuticals Inc

The latest public price target was made on Apr 12, 2024 by Akash Tewari from Jefferies , who expects REGN stock to rise by 17% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Akash Tewari
Jefferies
1 060 USD
Upside 17%
2 weeks ago
Apr 12, 2024
Regeneron Pharma (REGN) PT Raised to $1,060 at Jefferies
StreetInsider
Brian Abrahams
RBC Capital
1 189 USD
Upside 32%
3 weeks ago
Apr 11, 2024
RBC on Regeneron Pharma (REGN):'The Buying Opportunity Many Have Been Looking For, With Overdone DOJ Downside On Top Of Recent Weakness'
StreetInsider
Matthew Harrison
Morgan Stanley
1 115 USD
Upside 23%
1 month ago
Mar 13, 2024
Regeneron Pharma (REGN) PT Raised to $1,115 at Morgan Stanley, 'Numerous catalysts ahead; refreshing estimates'
StreetInsider
Brian Abrahams
BMO Capital
1 076 USD
Upside 19%
3 months ago
Jan 12, 2024
Regeneron Pharma's Pipeline Makes This Analyst Turn Bullish
Benzinga
Andrew Berens
Leerink Partners
976 USD
Upside 8%
1 year ago
Mar 27, 2023
SVB Leerink Upgrades Regeneron Pharma (REGN) to Outperform
StreetInsider
Akash Tewari
Jefferies
925 USD
Upside 2%
1 year ago
Mar 24, 2023
Jefferies Upgrades Regeneron Pharma (REGN) to Buy
StreetInsider
Unknown Analyst
EF Hutton
853 USD
Downside 6%
1 year ago
Feb 8, 2023
EF Hutton Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $853
Benzinga
Unknown Analyst
RBC Capital
787 USD
Downside 13%
1 year ago
Feb 6, 2023
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Lowers Price Target to $787
Benzinga
Unknown Analyst
Morgan Stanley
883 USD
Downside 2%
1 year ago
Feb 6, 2023
Morgan Stanley Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $883
Benzinga
Unknown Analyst
Leerink Partners
834 USD
Downside 8%
1 year ago
Feb 6, 2023
SVB Leerink Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $834
Benzinga
Show More Price Targets
Show Less Price Targets
Akash Tewari
Jefferies
Price Target 1 060 USD
Upside/Downside 17%
View Source
Brian Abrahams
RBC Capital
Price Target 1 189 USD
Upside/Downside 32%
View Source
Matthew Harrison
Morgan Stanley
Price Target 1 115 USD
Upside/Downside 23%
View Source
Brian Abrahams
BMO Capital
Price Target 1 076 USD
Upside/Downside 19%
View Source
Andrew Berens
Leerink Partners
Price Target 976 USD
Upside/Downside 8%
View Source
Akash Tewari
Jefferies
Price Target 925 USD
Upside/Downside 2%
View Source
Unknown Analyst
EF Hutton
Price Target 853 USD
Upside/Downside 6%
View Source
Unknown Analyst
RBC Capital
Price Target 787 USD
Upside/Downside 13%
View Source
Unknown Analyst
Morgan Stanley
Price Target 883 USD
Upside/Downside 2%
View Source
Unknown Analyst
Leerink Partners
Price Target 834 USD
Upside/Downside 8%
View Source
Show More Price Targets
Show Less Price Targets
Regeneron Pharmaceuticals Inc Competitors:
Price Targets
COX
Nicox SA
401% Upside
ABBV
Abbvie Inc
16% Upside
A
298380
ABL Bio Inc
39% Upside
BIOA B
BioArctic AB
86% Upside
COX
Nicox SA
401% Upside
ABBV
Abbvie Inc
16% Upside
A
298380
ABL Bio Inc
39% Upside
BIOA B
BioArctic AB
86% Upside
X
688278
Xiamen Amoytop Biotech Co Ltd
28% Upside
VIR
Vir Biotechnology Inc
277% Upside
SOBI
Swedish Orphan Biovitrum AB (publ)
22% Upside
4974
Takara Bio Inc
101% Upside

Revenue
Forecast

Revenue Estimate
Regeneron Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Regeneron Pharmaceuticals Inc's revenue is 16%. The projected CAGR for the next 3 years is 7%.

16%
Past Growth
7%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Regeneron Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Regeneron Pharmaceuticals Inc's operating income is 16%. The projected CAGR for the next 3 years is 15%.

16%
Past Growth
15%
Estimated Growth
Estimates Accuracy
-17%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Regeneron Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Regeneron Pharmaceuticals Inc's net income is 26%. The projected CAGR for the next 3 years is 14%.

26%
Past Growth
14%
Estimated Growth
Estimates Accuracy
-17%
Average Miss
What are analyst estimates?

See Also

Summary
REGN intrinsic value, competitors valuation, and company profile.
DCF Valuation
REGN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
REGN stock valuation using valuation multiples.
Wall Street Estimates
REGN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
REGN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is REGN's stock price target?
Price Target
1 069.29 USD

According to Wall Street analysts, the average 1-year price target for REGN is 1 069.29 USD with a low forecast of 727.2 USD and a high forecast of 1 248.45 USD.

What is Regeneron Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
7%

For the last 8 years the compound annual growth rate for Regeneron Pharmaceuticals Inc's revenue is 16%. The projected CAGR for the next 3 years is 7%.

What is Regeneron Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
15%

For the last 8 years the compound annual growth rate for Regeneron Pharmaceuticals Inc's operating income is 16%. The projected CAGR for the next 3 years is 15%.

What is Regeneron Pharmaceuticals Inc's Net Income forecast?
Projected CAGR
14%

For the last 8 years the compound annual growth rate for Regeneron Pharmaceuticals Inc's net income is 26%. The projected CAGR for the next 3 years is 14%.

ALPHA SPREAD
Join more than 133,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.